Opthea (OPT) said Tuesday it has appointed Parisa Zamiri as its chief medical officer, effective Oct. 7, and Tom Reilly as its chief financial officer, effective Oct. 28.
Zamiri most recently served as Complement Therapeutics' medical chief while Reilly was previously the CFO of Amarin (AMRN).
The company said it is continuing to prepare for the phase 3 topline data readouts of its lead product candidate sozinibercept, with readouts from its COAST study anticipated in early Q2 2025 and from its ShORe trial in mid-2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。